These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 21322778

  • 1. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [Abstract] [Full Text] [Related]

  • 2. New drugs for myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [Abstract] [Full Text] [Related]

  • 3. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Palumbo A, Mateos MV, Bringhen S, San Miguel JF.
    Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
    [Abstract] [Full Text] [Related]

  • 4. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P.
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [Abstract] [Full Text] [Related]

  • 5. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Management of older patients with multiple myeloma.
    Gay F, Palumbo A.
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J, Cibeira MT, Rosiñol L.
    Acta Oncol; 2005 Mar; 44(5):440-8. PubMed ID: 16118077
    [Abstract] [Full Text] [Related]

  • 10. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V, Palumbo A.
    Cancer J; 2009 Mar; 15(6):494-501. PubMed ID: 20010169
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New drugs in multiple myeloma.
    Berenson JR, Yellin O.
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [Abstract] [Full Text] [Related]

  • 13. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A.
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [Abstract] [Full Text] [Related]

  • 14. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M, Prince HM.
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [Abstract] [Full Text] [Related]

  • 15. Emerging drugs in multiple myeloma.
    Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P.
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [New treatment strategy of multiple myeloma for cure].
    Murakami H, Handa H.
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [Abstract] [Full Text] [Related]

  • 18. Management of relapsed and relapsed refractory myeloma.
    Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [Abstract] [Full Text] [Related]

  • 19. Novel therapies in myeloma.
    Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.